Background: Progressing stroke (PS) and Crescendo Transient Iachemic Attacks (CTIA) are generally accepted although unproven, indication for urgent anticoagulation and there remains evidence-free practice of intravenous heparin therapy in these patientMethods : Consecutive patients PS and CTIA admitted in Ghaem hospital, Mashhad during 2007-2008 enrolled in a prospective observational study. PS and CTIA patients underwent intravenous heparin therapy 1000 units per hour for 3 days without bolus dose. PS and CTIA patients who had a contraindication of intravenous hepain therapy received 80 mg Aspirin per day. Early clinical course including improvement, stabilization, deterioration and development of residual stroke was evaluated in two therapeutic groups of PS and CTIA patients.. Results: 170 PS patients (103 males, 67 females) with mean age 60.4±12.3 years and 88 CTIA patients (50 males, 38 females) with mean age 60.1± 6.8 years were investigated. 141 PS and 64 CTIA patients received short period intravenous heparinization. Distribution of subtypes of early clinical course between two therapeutic groups of PS and CTIA patients was significantly different; X 2 =10.487, df=2 , p=0.005 and X 2 =6.72, df=2 , p=0.035 respectively. Distribution of residual stroke in two therapeutic groups of PS and CTIA patients was not significantly different; X 2 =1.443, df= 1, p=0.23, OR=0.557 (0.212-1.462) and X 2 =1.01, df=1, p=0.315, OR=0.617 (0.24-1.587) respectively.Conclusion: PS and CTIA patients who received short period intravenous heparin therapy have significantly more probability of improvement and less probability of deterioration in their early clinical course.
INTRODUCTION
Neurological deficits of ischemic stroke are frequently unstable during early phase of stroke. Patients my show progressive deterioration with stepwise or nonstepwise fashions or fluctuations with periods of improvement 1 .
Stroke in evolution is a non-specific term and is not synonymous with thrombosis in evolution 1 . Almost 30% of stroke patients worsen after entery to the hospital 1 .
Common practice considers that heparin followed by warfarin is indicated if observation provides clear evidence of recognizable worsening of an ischemic neurology disability 2 . This practice has been based on incomplete and largely anectodal data 2 . In progressive stroke (PS), the focal ischemia worsens over several hours, or a day or two 1, 2 .
Progression of stroke in a stepwise fashion is easier to regard as stroke due to repeated episodes of thromboembolism than is an indolently PS 3, 4 . Patients exhibiting stepwise progression may speculatively be considered as likely to benefit from anticoagulation 3, 4 . Conversely, patients who are adding to their neurologic deficit in a nonstepwise progressing fashion probably are not exhibiting progressive thrombus formation and will not be expected to respond to anticoagulation 3, 4 . Brain edema accounts for most of the progression in the later situation 2 . Multiple or Crescendo Transient Ischemic Attacks (CTIA) are frequent in clinical practice. The term CTIA defined as occurance of multiple episodes over a few hours or days, often with increasing duration or severity 5 . Some studies suggest that CTIA may represent a condition of impending brain infarction 6 .
Common practice of medicine recommends short term anticoagulation in patients with CTIA without proven efficacy 5, 6 . CTIA and major TIA require urgent evaluation and admission of the patient 4 . This observational study compares the clinical course of PS and CTIA patients who receive short term intravenous heparin therapy with similar patients who take ultra low dose of Aspirin. 9 . PS and CTIA patients who had an initially abnormal coagulation tests were excluded 9 . Short term intravenous heparin therapy in these patients is a routine therapeutic strategy in our instituation 2, 5 . PS and CTIA patients with a contraindication of intravenous heparin therapy administered Aspirin 80 mg per day during hospitalization period 2, 5 . The National Institute of Health Stroke Scale (NIHSS) was detected in all of patients with PS and CTIA before heparinization and 3 days later 10 . The clinical course of these patients was categorized as improvement, stabilization and deterioration 11 .
MATERIALS AND METHODS

Consecutive
Improvement was defined as ≥3 points decrease and deterioration as ≥3 points increase in the second NIHSS 10,11 .
Other patients were assumed as stabilization group 10,11 . The same NIHSS assessment was perform in PS and CTIA patients who have taken Aspirin therapy 10, 11 . Presence of stroke at 3 days after anticoagulation therapy was evaluated in all of our patients with PS and CTIA. All of these patients had a repeated CT after anticoagulation therapy for investigation of a visible infarct. A residual stroke was defined as presence of ischemic focal neurological deficit lasting more than 24 hours or observation of a hypodense lesion in the CT corresponding to the manifestations 11 respectively. Figure 2 illustrates early clinical course of 88 CTIA patients in our two therapeutic groups . Motor, sensory, aphasic and amarotic nanifestations were found in 48%, 19%, 15% and 2% of our CTIA cases respectively. Two PS and one CTIA cases had minor hemorrhagic complications of intravenous anticoagulation including echymosis and hematuria 
DISCUSSION
Controlled clinical trials performed more than 30 yeats ago suggested a beneficial effect of anticoagulation therapy in PS patients 3, 4 . Based on the results of these trials, the indication for heparin therapy in this condition became widely accepted 2, 5 . Other randomized and observational studies have not been conclusive in regard to the indication of anticoagulation in PS 12 . The data in aggregate suggested that heparin reduces the risk of PS 1,2,12 .
The lack of precise criteria for entry and outcome, non-blinded observation and small number of patients makes these studies inadequate by current methodological standards 2, 5, 13 . The main reason that 72 hours was selected as cut off point in assessment of our patients is that progression period in usually completed in 72 hours 1 . At the other side, some of these patients are practically discharged in 3-4 days after anticoagulation therapy and extention of hospitalization time only for research is not possible ethically. Use of heparin in PS patients is still a matter of controversy in recent years 14 .
Although short term intravenous heparinization demonstrated non significant influence on development of residual stroke in our PS patients, however it has confirmed a significant influence on early stroke course in PS patients. PS patients who have been on short period intravenous heparinization had significantly more probability for improvement and less probability for deterioration. Heparin is widely used for clustering or CTIA 2 . This therapeutic strategy for CTIA has been largely for theoretical reasons and by extrapolation from the results of studies of anticoagulation for PS 2, 5 . Although heparin appears to be the prefered treatment for CTIA, the data supporting its efficacy are meager and come from old and limited studies 15 . However, intravenous heparinization has been shown to be a safe therapy in these cases 15 . Despite reports of safety in administration of bolus of intravenous heparin while initiating heparin therapy 16 , bolus dose of heparin was not adminstered in our PS and CTIA patients and none of them developed major hemorrhagic complications. There remains relatively evidence-free practice of using heparin in patients with CTIA 14 . Although short period intravenous heparnization was associated with a non significant effect on development of residual stroke in our CTIA patients, however our CTIA patients who have been on this therapy had significantly more probability of improvement and less probability of deterioration in their early clinical course evaluation. 
